Personalized Cancer Therapy: Repurposing and in vitro drug screens
The Centre for Cancer Biomarkers (CCBIO) and Oslo Cancer Cluster (OCC) cordially invite you to a joint R&D Network titled "Personalized Cancer Therapy: Repurposing and in vitro drug screens" taking place November 10th in Bergen.
Main content
The meeting is organized as a joint CCBIO and Oslo Cancer Cluster event.
Drug repurposing and in vitro drug screening
International and Norwegian experts will present and discuss trends and examples in oncological drug repurposing (also sometimes called drug repositioning) and in vitro drug screening. In vitro drug screens have been used as a research tool for therapy development in decades, but robotics and bioinformatics has made it feasible to test more agents and even combinations. The culture conditions of these screens have improved to better reflect the tumor environment. Therefore several groups have started small clinical trials for selecting the therapeutic agent through screens of cells from refractory/relapsed cancers.
Repurposed therapeutics have increasingly emerged as experimental options, sometimes based on high end in vitro drug screens. Both approaches can address existing unmet patient needs and provide new treatment options for specific cancers and individual patients. The program features speakers with complementary backgrounds and expertise from academia and industry. The networking parts allow you to connect to the speakers and meet your colleagues in an informal setting.
We are looking forward to a stimulating and interactive meeting and to seeing you in Bergen!
Registration
The meeting is open, free of charge and lunch is included. Please register via the Oslo Cancer Cluster website here.
Program: (see also printer friendly program here)
Moderator: Bjørn Tore Gjertsen, Co-Director and Professor, Centre for Cancer Biomarkers (CCBIO)
10:30–11:00 |
| Registration and coffee |
11:00–11:10 |
| Welcome and introduction Ketil Widerberg, General Manager Oslo Cancer Cluster and Bjørn Tore Gjertsen, CCBIO |
11:10 – 11:25 |
| Setting the scene: Repurposing in glioblastoma - clinical considerations and novel insights? Per Øyvind Enger, UiB and Haukeland University Hospital |
11:25 – 11:35 |
| Setting the scene: the patient perspective Lars Haakon Søraas |
11:35–12:15 |
| Repurposing and clinical trials in cancer – academic trials from a charity perspective Pan Pantziarka, AnticancerFund, UK |
12:15 – 13:15 |
| NETWORKING LUNCH |
13:15–13:30 |
| Sarcoma therapy development: Next gen sequencing and implications for drug choice Eva Wessel Stratford, Oslo University Hospital |
13:30 – 13:45 |
| Drug screening for acute myeloid leukemia patients Jorrit Enserink, Oslo University Hospital |
13:45–14:00 |
| In vitro drug screen in B-cell malignancies Kjetil Taskén, Norwegian Center for Molecular Medicine (NCMM), Oslo |
14:00–14:15 |
| Biotech perspective – Case Study Emmet Mc Cormack, Kinn Therapeutics, Bergen |
14:15 – 14:30 |
| COFFEE BREAK & Opportunity for CCBIO Seminar and BMED380 participants to join the program |
14:30 – 14:55 |
| International Keynote: “In vitro drug screen in acute myeloid leukemia" Caroline Heckman, FIMM, Helsinki |
14:55 – 15:15 |
| Case study: Repurposing of Quinacrine for treatment of acute myeloid leukemia Anna Eriksson, Uppsala University, Dept. of Medical Sciences |
15:15 – 15:30 |
| Drug repurposing: an opportunity for developing better drugs for children with cancer Cesare Spadoni, Chairman aPODD (accelerating Paediatric Oncology Drug Development) |
15:30 – 16:00 |
| Discussion and Wrap up |
From 16:00 |
| MINGLING with FINGER FOOD |
